Recommended for

• 1. Adults seeking cancer screening at early stage.
• 2. Individuals with a family history of cancer or concerns about cancer development.
• 3. Adults willing to take cancer screening tests but fear invasive endoscopy or imaging tests with radiation exposure.
• 4. Individuals needing further testing because of inconclusive results from other screening tests.

CancerFind detect 8 cancer types
with a simple blood draw

(Colorectal Cancer, Gastric Cancer, Liver Cancer, Pancreatic Cancer,
Lung Cancer, Breast Cancer, Ovarian Cancer, Prostate Cancer)

• 

  Colorectal Cancer

• 

  Gastric Cancer

• 

  Liver Cancer

• 

  Pancreatic Cancer

• 

  Lung Cancer

• 

  Breast Cancer

• 

  Ovarian Cancer

• 

  Prostate Cancer

CancerFind Test Process

• 

  Blood Sampling

  A Simple Blood Draw

  20mL of blood is sampled for the CancerFind test.
  The blood is Stored in dedicated cfDNA tube.

• 

  Genetic Analysis

  Advanced AI-Driven Genomic Precision Analysis

  cfDNA in the blood is extracted and amplified to run Next Generation Sequencing for detecting mutations.

• 

  Clinical Report

  Results delivered in 3 weeks

  The presence or absence of ctDNA is delineated. When a cancer signal is detected, information regarding the predicted primary tumor site is provided.

Features of CancerFind

Detection of a trace amount of cancer-derived DNA using innovative liquid Topsy technology

Cancer is initially very small in size, only a trace amount of circulating tumor-derived DNA exist in the blood. To detect cancer early, it is crucial to comprehensively analyze changes in the genome that occur due to cancer across a wide range. CancerFind has maximized the performance of early cancer detection through innovative next-generation liquid biopsy analysis technology.

• VS. Imaging Tests

  Imaging test requires separate tests for different organs and can be challenging to repeat regularly. Furthermore, they have limitations in detecting small-sized cancers at an early stage.

  · CancerFind test conducted through a convenient blood draw. and enable to detect cancers smaller than 1cm in size.

• VS. Protein tumor markers

  Conventional blood protein cancer markers(e.g., CEA, CA- 19-9, PSA, etc.) can increase due to factors other than cancer, leading to a notable false-positive ratio and reduced accuracy.

  · CancerFind enables accurate detection of cancer signal by analyzing multi-omics genomic patterns of ctDNA.

• VS. Conventional blood- based hereditary cancer tests

  Conventional blood-based hereditary cancer tests indirectly examine genetic mutations related to hereditary cancers in blood cells, not directly derived from cancer cells. These indirect tests cannot confirm the presence of cancer at the time of testing.

  · CancerFind directly analyzes the characteristics of ctDNA in real-time with high accuracy and specificity.

CancerFind™ Testing Facilities